

University of Groningen

## Quality of Life in Male Breast Cancer

Schröder, Carolien P; van Leeuwen-Stok, Elise; Cardoso, Fatima; Linderholm, Barbro; Poncet, Coralie; Wolff, Antonio C; Bjelic-Radusic, Vesna; Werutsky, Gustavo; Abreu, Miguel H; Bozovic-Spasojevic, Ivana

*Published in:*  
The Oncologist

*DOI:*  
[10.1093/oncolo/oyad152](https://doi.org/10.1093/oncolo/oyad152)

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2023

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Schröder, C. P., van Leeuwen-Stok, E., Cardoso, F., Linderholm, B., Poncet, C., Wolff, A. C., Bjelic-Radusic, V., Werutsky, G., Abreu, M. H., Bozovic-Spasojevic, I., den Hoed, I., Honkoop, A. H., Los, M., Leone, J. P., Russell, N. S., Smilde, T. J., van der Velden, A. W. G., Van Poznak, C., Vleugel, M. M., ... Ruddy, K. J. (2023). Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG). *The Oncologist*, 28(10), e877–e883. <https://doi.org/10.1093/oncolo/oyad152>

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG)

Carolien P. Schröder<sup>\*1</sup>, Elise van Leeuwen-Stok<sup>2</sup>, Fatima Cardoso<sup>3</sup>, Barbro Linderholm<sup>4</sup>, Coralie Poncet<sup>5</sup>, Antonio C. Wolff<sup>6</sup>, Vesna Bjelic-Radicic<sup>7</sup>, Gustavo Werutsky<sup>8</sup>, Miguel H. Abreu<sup>9</sup>, Ivana Bozovic-Spasojevic<sup>10</sup>, Irma den Hoed<sup>11</sup>, Aafke H. Honkoop<sup>12</sup>, Maartje Los<sup>13</sup>, Jose P. Leone<sup>14</sup>, Nicola S. Russell<sup>15</sup>, Tineke J. Smilde<sup>16</sup>, Annette W.G. van der Velden<sup>17</sup>, Catherine Van Poznak<sup>18</sup>, Marije M. Vleugel<sup>19</sup>, Rachel L. Yung<sup>20</sup>, Corneel Coens<sup>5</sup>, Sharon H. Giordano<sup>21</sup>, Kathryn J. Ruddy<sup>22</sup>

<sup>1</sup>Department Medical Oncology, Netherlands Cancer Institute Amsterdam and University Medical Center Groningen, The Netherlands

<sup>2</sup>Dutch Breast Cancer Trialists' Research Group (BOOG), The Netherlands

<sup>3</sup>Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal

<sup>4</sup>Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden and Swedish Association of Breast Oncologists (SABO), Sweden

<sup>5</sup>European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium

<sup>6</sup>Department of Medical Oncology, Johns Hopkins, Baltimore, MD, USA

<sup>7</sup>Breast Unit, Helios University Clinic, Wuppertal, University Witten/Herdecke, Germany

<sup>8</sup>Latin American Cooperative Oncology Group, Porto Alegre, Brazil

<sup>9</sup>Department of Medical Oncology, Portuguese Institute of Oncology of Porto, Porto, Portugal

<sup>10</sup>Department of Medical Oncology, Institute of Oncology and Radiology, Belgrade, Serbia

<sup>11</sup>Department of Medical Oncology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, The Netherlands

<sup>12</sup>Department of Medical Oncology, Isala, Zwolle, The Netherlands

<sup>13</sup>Department of Medical Oncology, St. Antonius Ziekenhuis, Utrecht, The Netherlands

<sup>14</sup>Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

<sup>15</sup>Department of Radiotherapy, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands

<sup>16</sup>Department of Medical Oncology, Jeroen Bosch Ziekenhuis's Hertogenbosch, The Netherlands

<sup>17</sup>Department of Medical Oncology, Martini Ziekenhuis, Groningen, The Netherlands

<sup>18</sup>Department of Medical Oncology, University of Michigan, Ann Arbor, MI, USA

<sup>19</sup>Department of Medical Oncology, Waterlandziekenhuis, Purmerend, The Netherlands

<sup>20</sup>Department of Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA

<sup>21</sup>Department of Health Services Research and Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA

<sup>22</sup>Department of Oncology, Mayo Clinic, Rochester, MN, USA

\*Corresponding author: Carolina P. Schröder, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. Tel: +31205128760; Email: [c.schroder@nki.nl](mailto:c.schroder@nki.nl)

## Abstract

**Introduction:** Prospective data about quality of life (QoL) in men with breast cancer (BC) are lacking. A prospective registry (EORTC10085) of men with all BC stages, including a QoL correlative study, was performed as part of the International Male Breast Cancer Program.

**Methods:** Questionnaires at BC diagnosis included the EORTC QLQ-C30 and BR23 (BC specific module), adapted for men. High functioning and global health/QoL scores indicate high functioning levels/high QoL; high symptom-focused measures scores indicate high symptoms/problems levels. EORTC reference data for healthy men and women with BC were used for comparisons.

**Results:** Of 422 men consenting to participate, 363 were evaluable. Median age was 67 years, and median time between diagnosis and survey was 1.1 months. A total of 114 men (45%) had node-positive early disease, and 28 (8%) had advanced disease. Baseline mean global health status score was 73 (SD: 21), better than in female BC reference data (62, SD: 25). Common symptoms in male BC were fatigue (22, SD: 24), insomnia (21, SD: 28), and pain (16, SD: 23), for which women's mean scores indicated more burdensome symptoms at 33 (SD: 26), 30 (SD: 32), and 29 (SD: 29). Men's mean sexual activity score was 31 (SD: 26), with less sexual activity in older patients or advanced disease.

**Conclusions:** QoL and symptom burden in male BC patients appears no worse (and possibly better) than that in female patients. Future analyses on impact of treatment on symptoms and QoL over time, may support tailoring of male BC management.

**Key words:** male breast cancer; quality of life; prospective study; symptom assessment.

Received: 29 August 2022; Accepted: 22 April 2023.

© The Author(s) 2023. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

## Implications for Practice

In this prospective male breast cancer (BC) registry, baseline quality of life (QoL) and symptom burden in male patients with BC appears no worse (and possibly better) than that in female patients. Future analyses of later surveys from this study will assess the impact of specific treatments on changes in symptoms and QoL over time. These data will be useful in efforts to tailor treatments and target interventions for male BC.

## Introduction

Male breast cancer (BC) is a rare disease that accounts for less than 1% of all cancers in men and about 1% of all BC.<sup>1</sup> Due to the rarity of the disease and the common exclusion of men from BC studies,<sup>2</sup> male BC-focused basic and clinical research is limited. Although recently a male BC specific subset analysis of a randomized phase III trial was reported,<sup>3</sup> most available data come from observational retrospective studies.<sup>4-6</sup> To improve our understanding of male BC biology and to optimize clinical management, a global collaborative effort, the *International Male Breast Cancer Program*, was launched in 2006. This program published the largest retrospective series to date of male BC patients with centrally reviewed clinical data and tumor samples<sup>7</sup>; this identified changes over time in male BC treatments, mirroring those in female BC.<sup>8</sup> Subsequently, the International Male Breast Cancer Program launched a prospective registry of newly diagnosed patients with male BC with clinical data and tumor samples (EORTC10085/TBCRC029/BIG2-07/NABCG). Enrolling from 2013 to 2017 in 7 European and 3 South American countries, and in the United States ([Supplementary Table S1](#)), this study aimed to gather information about modern tumor biology and treatments, and it included a correlative substudy to assess quality of life (QoL) and symptom burden, which have been woefully understudied in male BC.

Limited retrospective data are available regarding symptoms and QoL in men with breast cancer. In a Behavioral Risk Factor Surveillance System telephone survey comparing 198 men without cancer and 66 men with a history of BC who were diagnosed on average 12 years ago, poorer physical, and mental health was identified in BC survivors. Obesity, diabetes, and activity limitations due to a physical, mental, or emotional problems were also more common after BC.<sup>9</sup> Endocrine therapy side effects and persistence rates have been evaluated in several small studies,<sup>10-13</sup> but while male BC patients clearly have specific unmet needs for information in this setting,<sup>14</sup> QoL and physical and emotional symptoms near the time of diagnosis are still understudied. In one study of 78 men undergoing an evaluation for a breast abnormality in the United Kingdom, approximately 30% reported feeling embarrassed to see their doctor, and one fourth reported anxiety related to their diagnosis.<sup>15</sup>

We designed the QoL substudy to address gaps in knowledge regarding QoL and symptom burden around the time of diagnosis of male BC and over time thereafter to inform optimal treatment and survivorship care. Here we report the results of the baseline questionnaires of men who participated in the QoL substudy.

## Patients and Methods

### Study Design

Men with histologically proven breast cancer, age  $\geq 18$  years, newly presenting at a participating center or within 3

months prior to center activation (irrespective of the stage of disease, initial diagnosis date, or treatment received), and enrolling in the prospective registry of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG) were eligible for the QoL substudy. Written informed consent was required: either one general consent for both parent and QoL study (in the Netherlands) or separate consents for both parent and QoL study for other participating countries (Switzerland, Greece, Ireland, Portugal, Serbia, Sweden, United States, Brazil, Mexico, and Peru).

### Questionnaires

QoL was measured using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 version 3) and items from EORTC QLQ-BR23 and EORTC-PR25.<sup>16</sup> The EORTC QLQ-C30 is a well-validated 30-item scale that measures the primary dimensions of QoL, as well as specific cancer-related symptoms. It is composed of a global health/QoL scale, functioning scales (physical, role, emotional, cognitive, and social functioning scale), and symptoms scales/items (fatigue, nausea and emesis, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The Breast Cancer Modular Supplement (EORTC QLQ-BR23) is a validated 23-item breast cancer-specific questionnaire that should be added to the EORTC QLQ-C30 to obtain additional information about QoL and symptoms that are prevalent in BC patients. It contains 5 multi-item scales to assess body image, sexual functioning, systemic therapy side effects, arm symptoms, and breast symptoms, as well as single items to assess sexual enjoyment, future perspective, and upset by hair loss. The multi-item scales and single items are divided into 2 groups: functional (body image, sexual functioning, sexual enjoyment, and future perspective) and symptom-focused (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). In consultation with the EORTC headquarters QoL department, 4 of the BR23 items that are only appropriate for women (regarding physical attraction, feeling less feminine, difficulty looking at yourself naked, and dissatisfaction with your body) were omitted, gendered language in the instructions was edited to be appropriate for men, and 11 additional items from the PR25 (a 25-item modular supplement developed and validated for prostate cancer patients) were used to assess function (sexual activity and sexual functioning) and hormonal treatment-related symptoms (see [Supplementary Fig. S1](#) for complete instrument administered). Scores for all scales and single items range from 0 to 100. High scores for functioning and global health/QoL measures indicate high/healthy levels of functioning/high QoL, whereas high scores for symptom-focused measures indicate a high level of symptoms/problems.

### Statistical Analysis

Questionnaire forms were analyzed centrally by the EORTC statistics department. Descriptive analysis was conducted in patients with baseline QoL forms completed within 30

days of date of registration to capture baseline status accurately. As information related to the course of QoL in time is not yet available, the clinical meaning of the QoL data was assessed by comparing<sup>17</sup> it to a normative (reference) population of men in 6 European general population studies,<sup>18</sup> and a population of 2782 women with all stages of BC (all stages) used for EORTC QLQ-C30 reference values.<sup>19</sup> Scores were reflected as mean (SD), or median (interquartile range, IQR).

## Results

### Study Enrollment

Between October 24, 2013 and March 01, 2017, a total of 557 patients were enrolled in the international prospective registry, the parent study (see Fig. 1), 445 of which at 46 sites participated in the QoL substudy. Consent forms were received from 422/445 men (95%) for the QoL substudy. The clinical database was locked on November 02, 2017 for this analysis. Baseline survey compliance was 95% (399/422), and 363/399 (91%) of patients completed that survey within 30 days of registration, making them eligible for analysis. Median age was 67 years (range 33-92). There were 114 respondents (45%) with node-positive early disease (M0) and 28 respondents (8%) with advanced disease (M1). Patient- and treatment characteristics are shown in Table 1. Median time from diagnosis to baseline survey was 1.1 months (range -0.8 to 206.0). Of 363 evaluable men, 193 (53.2%) men received at least one treatment modality prior to baseline QoL completion: 180 (49.6%) had received surgery, 24 (7%) had received

radiotherapy, and 70 (19.3%) had started on systemic therapy (median interval with surgery 43 days, Q1-Q3: 24.5-89; 118 days with radiotherapy, Q1-Q3: 36.5-744; 43 days with systemic therapy, Q1-Q3: 13-121; see Supplementary Fig. S2 for combinations of therapies). The majority of patients were from Europe (75%), followed by the United States (21%) and South America (4%). More detailed inclusion data by country are shown in Supplementary Table S1.

### EORTC QLQ-C30 Scores

QoL and symptom scores at baseline in the overall population are shown in Table 2. Mean global health status score was 73 (SD: 21) and mean social functioning score was 85 (SD: 22). Men's most commonly reported symptoms included fatigue (mean score 22, SD: 24), insomnia (mean score 21, SD: 28), and pain (mean score 16, SD: 23). With regard to items from the PR25 questionnaire, mean sexual activity score was 31 (SD: 26), and in those who were sexually active, mean sexual function score was 80 (SD: 18). Only 4 men were 40 or younger; they reported more fatigue, nausea/vomiting, pain, appetite loss, constipation, and financial problems than older men. There were no substantial differences in QoL or symptom burden between those with advanced stage and those with early-stage disease. In patients who were sexually active, sexual functioning tended to be worse in those with advanced disease, with mean score 68 (SD: 22) versus 81 (SD: 17) for those with early-stage disease. The effects of age and disease stage are shown in greater detail in Supplementary Tables S2 and S3.




Figure 1. CONSORT diagram.

**Table 1.** Baseline characteristics.

|   | All patients<br>(N = 363) |
|---|---------------------------|
|   | N (%)                     |
| Patient and tumor characteristics                   |                           |
| Year of diagnosis                                   |                           |
| 1996-2000   | 2 (0.6)                   |
| 2001-2005   | 2 (0.6)                   |
| 2006-2010   | 2 (0.6)                   |
| >2011   | 337 (92.8)                |
| Missing   | 20 (5.5)                  |
| Time from diagnosis to QoL form (months)            |                           |
| Median  | 11.5                      |
| Range   | 0.5-214.5                 |
| Q1-Q3   | 5.1-25.2                  |
| Mean (SD)   | 18.10 (22.91)             |
| N obs   | 343                       |
| Age at diagnosis                                    |                           |
| Median  | 67.3                      |
| Range   | 32.6-92.3                 |
| N obs   | 343                       |
| Age at diagnosis (categories)                       |                           |
| ≤40   | 4 (1.1)                   |
| 41-50   | 31 (8.5)                  |
| 51-65   | 118 (32.5)                |
| 66-75   | 107 (29.5)                |
| >75   | 83 (22.9)                 |
| Missing   | 20 (5.5)                  |
| M status  |                           |
| M0  | 253 (69.7)                |
| M1  | 28 (7.7)                  |
| Mx  | 82 (22.6)                 |
| If M0, LN status (path., clin. if path. is missing) |                           |
| Negative  | 136 (53.8)                |
| Positive  | 114 (45.1)                |
| Missing   | 3 (1.2)                   |
| Local and systemic treatments                       |                           |
| Surgery to the breast/lymph nodes <sup>a</sup>      |                           |
| Breast conserving                                   | 9 (5)                     |
| Mastectomy  | 170 (94.4)                |
| Lymph node only                                     | 1 (0.6)                   |
| Radiotherapy <sup>a</sup>                           | 24 (6.6)                  |
| Systemic therapy <sup>a</sup>                       |                           |
| Chemotherapy  |                           |
| No  | N = 70                    |
| Yes   | 45 (64.3)                 |
| Yes   | 25 (35.7)                 |
| Endocrine therapy                                   |                           |
| No  | N = 70                    |
| Yes   | 18 (25.7)                 |
| Yes   | 51 (72.9)                 |
| Targeted therapy                                    |                           |
| No  | N = 70                    |
| Yes   | 61 (87.1)                 |
| Yes   | 7 (7.1)                   |

Surgery or radiotherapy prior to baseline QoL survey; systemic treatment initiated prior to baseline QoL survey.

## Comparison to Reference Groups

Fig. 2A displays the EORTC QLQ-C30 functional scales in patients with male BC compared to those previously found in female patients with BC and in a reference healthy male population. In the historical sample of women with BC, mean global health status score was 61.8 (SD: 24.6) in 2782 women with mixed stage and 65 (SD: 23) in the subgroup of 464 women with stage 1-2 tumors, inferior to those we found in male BC. In a reference population of healthy men, mean global health status score was 71 (SD: 23), comparable to that we identified in men with BC. Mean social functioning scores were 77 (SD: 27) and 88 (SD: 21) in the reference populations of women with BC and healthy men, respectively. Fig. 2B shows the EORTC QLQ-C30 symptom scales in the same populations. Although fatigue, insomnia, and pain were most commonly reported symptoms with highest scores in both male and female BC patients, women's mean scores indicated more burdensome symptoms (mean: 33 [SD: 26], 30 [SD: 32], and 29 [SD: 29] respectively).

## Discussion

This study represents a significant step toward an improved understanding of QoL in male BC patients. Unlike previous QoL research focusing on long-term survivors, we have assessed QoL around the time of diagnosis, and we have done so in a diverse, international population from 13 countries using a survey comprised of validated components and translated into multiple languages. This study demonstrates that it is possible to perform international prospective trials in patients with a rare cancer. The relatively high response percentage may reflect an understanding on the part of male BC patients that research is lacking to inform the management of this rare disease.

Importantly, sexual activity is affected by advanced disease stage and age, consistent with another smaller study that surveyed men later in survivorship.<sup>20</sup> However, despite concerns that we might find substantial emotional distress in this population related to sexual dysfunction and having been diagnosed with a cancer that is strongly associated with female gender, there was little evidence of poor emotional or social functioning. Many men had not yet started systemic treatment for their cancers at the time of survey completion, which may account in part for the preserved QoL scores (the side effects of endocrine therapy had not started yet in those cases).

Our data are consistent with the findings of a survey of 84 men recently discharged from one of 51 hospitals in Germany after treatment of primary breast cancer in 2006-2011. Compared to 20 589 women with BC, an adjusted analysis showed that male patients scored significantly better on physical functioning, role functioning-physical and emotional, bodily pain, vitality, social functioning, and mental health. However, compared to healthy men, these men with recently diagnosed BC scored worse, particularly with regard to emotional and physical role functioning.<sup>18,21</sup>

A Dutch study of men with prostate cancer shows that a cancer diagnosis itself, even before treatment begins, can adversely impact HRQoL.<sup>22</sup> In this assessment of 80 men, it was evident that the decision to undergo more aggressive prostate cancer treatment was associated with greater decrements in HRQoL, perhaps because fear of the toxicities of treatment is detrimental to mental health. Interestingly, in other studies

**Table 2.** EORTC-QLQ-C30, B23, and PR25 questionnaire data.


|  | N   | Mean (SD)   | Median (range)    |
|--|-----|-------------|-------------------|
| EORTC-QLQ-C30 functional scales        |     |             |                   |
| Physical functioning                   | 361 | 85.3 (20.9) | 93.3 (0.0-100.0)  |
| Role functioning                       | 361 | 80.8 (27.7) | 100.0 (0.0-100.0) |
| Emotional functioning                  | 362 | 77.0 (22.4) | 86.3 (0.0-100.0)  |
| Cognitive functioning                  | 362 | 87.3 (17.6) | 100.0 (0.0-100.0) |
| Social functioning                     | 362 | 84.9 (22.1) | 100.0 (0.0-100.0) |
| Global health status/ QoL              | 362 | 73.4 (20.8) | 75.0 (0.0-100.0)  |
| EORTC-QLQ-C30 symptom scales           |     |             |                   |
| Fatigue                                | 362 | 21.7 (23.8) | 11.1 (0.0-100.0)  |
| Nausea/vomiting                        | 362 | 3.4 (12.4)  | 0.0 (0.0-100.0)   |
| Pain                                   | 362 | 15.8 (22.7) | 0.0 (0.0-100.0)   |
| Dyspnoea                               | 361 | 13.1 (23.3) | 0.0 (0.0-100.0)   |
| Insomnia                               | 360 | 21.5 (28.4) | 0.0 (0.0-100.0)   |
| Appetite loss                          | 358 | 8.0 (18.6)  | 0.0 (0.0-100.0)   |
| Constipation                           | 362 | 8.1 (20.1)  | 0.0 (0.0-100.0)   |
| Diarrhoea                              | 359 | 5.7 (16.0)  | 0.0 (0.0-100.0)   |
| Financial problems                     | 362 | 11.5 (23.9) | 0.0 (0.0-100.0)   |
| EORTC-QLQ-BR23 functional scale        |     |             |                   |
| Future perspectives                    | 354 | 62.0 (29.5) | 66.7 (0.0-100.0)  |
| EORTC-QLQ-BR23 symptom scales          |     |             |                   |
| Systematic therapy side effects        | 359 | 8.9 (12.4)  | 4.8 (0.0-85.7)    |
| Breast symptoms                        | 357 | 17.6 (17.7) | 16.7 (0.0-100.0)  |
| Arm symptoms                           | 357 | 12.8 (19.0) | 0.0 (0.0-100.0)   |
| Upset by hair loss                     | 31  | 22.6 (26.4) | 33.3 (0.0-100.0)  |
| EORTC-QLQ-PR25 functional scales       |     |             |                   |
| Sexual activity                        | 347 | 31.0 (25.6) | 33.3 (0.0-100.0)  |
| If sexually active, sexual functioning | 168 | 79.6 (17.8) | 83.3 (25.0-100.0) |
| EORTC-QLQ-PR25 symptom scale           |     |             |                   |
| Hormonal symptoms                      | 360 | 7.8 (9.7)   | 5.6 (0.0-61.1)    |

High scores for functioning and global health/QoL measures indicate high/healthy levels of functioning/high QoL. High scores for symptom-focused measures indicate a high level of symptoms/problems.

focused on long-term survivors of prostate cancer, HRQoL does not seem to differ substantially by treatment.<sup>23</sup>

Limitations of our study include the unavailability of a validated questionnaire specifically designed for men with BC. We used the extensively validated EORTC QLQ-C30 and also added the adapted EORTC QLQ-BR23, plus select items from the QLQ-PR25, to capture the experiences of men with BC, including with regard to sexual functioning (for which the BR23 does not apply to men) and side effects of endocrine therapy. Although the EORTC QLQ-C30, BR23, and PR25 were already fully validated in all of the languages we needed for this study, the resulting merged questionnaire has not yet been validated. Of note, the ongoing EORTC QLQ 002/2019 study aims at developing a male BC specific BC module, based on input from male BC patients and health care professionals to determine which issues are most relevant for this patient group. Another limitation is that inclusion was not based on diagnosis date, so some patients had already received treatment at the time of the survey. Although, as expected, treatments consisted mostly of surgery and to a lesser extent radio- or systemic therapy, this could have affected symptoms

and QoL. The lack of substantial differences in QoL or symptom burden between those with advanced stage and those with early-stage disease should be interpreted with caution in light of the relatively low number of patients with advanced disease. Furthermore, comparing male BC to female BC has its limitations. The EORTC QoL female reference population had different characteristics (62% were under age 60; 41% had recurrent or metastatic disease, 31% had stage 1-2 disease, and 29% had unknown stage). In our study, 8% of patients had known advanced disease and 23% had unknown stage. These differences in stage could have resulted in patient-reported QoL differences. Also, differences in BC management, such as the low rate of breast conservation in men, may have influenced symptoms. Nonetheless, gender differences in QoL scores independent of breast cancer may contribute to differences between patients with female and male BC. This has been observed also in other tumor types. Therefore, comparisons of these QoL and symptom data to historic controls should be regarded as only hypothesis-generating. However, they help to integrate our results with other existing data about QoL.



**Figure 2.** (A) EORTC QLQ-C30 functional scales in male patients with BC, a healthy male reference population, and female patients with BC. High scores indicate high/healthy levels of functioning. (B) EORTC QLQ-C30 symptom scales in male patients with BC, a healthy male reference population and female patients with BC. High scores indicate a high level of symptoms/problems.

## Conclusion

This large prospective registry substudy demonstrates that overall QoL is good in men who were recently diagnosed with breast cancer, but some still suffer appetite loss, fatigue, and insomnia. Sexual functioning may also be an issue. In our future analyses of later surveys, the impact of specific treatments on changes in symptoms and QoL over time will be assessed. It will be important to use the data collected via this and our upcoming serial QoL assessments to help develop interventions to improve clinical care for men with breast cancer.

## Acknowledgments

We are grateful to all patients, investigators who participated in the study, all national coordinating centers and groups (EORTC-Breast Cancer Group, BOOG, SABO, Cancer Trials Ireland, SAKK, TBCRC, LACOG), and many independent sites from Spain.

## Funding

The International Male Breast Cancer Program and this work is supported by grants from the Breast Cancer Research Foundation, the Dutch Pink Ribbon Foundation (2012.WO42.C157), the EORTC Cancer Research Fund, the European Breast Cancer Council, Susan G. Komen for the Cure, the Swedish Breast Cancer Association (BRO),

Palga Group, AVON Foundation. K.J.R. was supported by a training grant under KL2TR002379-01 from the National Center for Advancing Translational Sciences (NCATS) of the NIH (its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH).

## Conflict of Interest

Carolien P. Schröder reported research funding from the Dutch Cancer Society, Dutch Pink Ribbon Foundation, Pfizer, and Siemens (to institution), clinical trial support by Roche, Genentech, Pfizer, SNS Oncology, G1 Therapeutics, Abbvie, Synthon, CytoMx Therapeutics, Seagen, and Dragonfly (to institution). Elise van Leeuwen-Stok reported research funding from the Dutch Pink Ribbon Foundation. Fatima Cardoso reported consulting/advisory relationships with Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, MacroGenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, and Touchime. Barbro Linderholm reported consulting/advisory relationships with AstraZeneca, Pfizer, Merck, Eli Lilly, Daiichi Sankyo/UCB Japan, and Gilead. Ivana Bozovic-Spasojevi reported honoraria for participation in Advisory Board from Roche and AstraZeneca, receipt of honoraria as invited speaker from AstraZeneca, Novartis, Pfizer, Roche, and PharmaSwiss, and receipt of personal and institutional financial interest as local PI from Roche. Jose P. Leone reported research funding from Kazia Therapeutics (to the institution) and consulting for Minerva Biotechnologies. Rachel L. Yung reported research funding to University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA from Pfizer. Sharon H. Giordano reported research funding from NIH, CPRIT, and Komen. Kathryn J. Ruddy reported ownership interest (receiving royalties) from UpToDate and intellectual property (spouse is co-inventor of a technology licensed by Mayo Clinic to Alivacor). The other authors indicated no financial relationships.

## Author Contributions

Conception/design: C.P.S., E.v.L.S., F.C., A.C.W., V.B.R., C.C., S.H.G., K.J.R. Provision of study material or patients: C.P.S., E.v.L.S., F.C., B.L., A.C.W., V.B.R., G.W., M.H.A., I.B.S., I.H., A.H.H., M.L., D.M., N.S.R., T.J.S., A.W.G.v.d.V., C.V.P., M.M.V., R.L.Y., S.H.G., K.J.R. Collection and/or assembly of data: C.P.S., E.v.L.S., F.C., C.P., C.C., S.H.G., K.J.R. Data analysis and interpretation: C.P.S., F.C., C.P., C.C., K.J.R. Manuscript writing: C.P.S., K.J.R. Final approval of manuscript: All authors.

## Previous Presentation

Previously presented in part at the San Antonio Breast Cancer Symposium 2017.

## Data Availability

The data underlying this article will be shared on reasonable request to the corresponding author.

## Supplementary Material

Supplementary material is available at *The Oncologist* online.

## References

- Giordano SH. Breast cancer in men. *N Engl J Med*. 2018;379(14):1385-1386. <https://doi.org/10.1056/NEJMc1809194>.
- Corrigan KL, Mainwaring W, Miller AB, et al. Exclusion of men from randomized phase III breast cancer clinical trials. *The Oncologist*. 2020;25(6):e990-e992. <https://doi.org/10.1634/theoncologist.2019-0871>.
- Campone M, De Laurentiis M, Zamagni C, et al. Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb complement-1 trial. *Breast Cancer Res Treat*. 2022 Feb 25;193(1):95-103. <https://doi.org/10.1007/s10549-022-06543-1>.
- Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. *Cancer*. 2004;101(1):51-57. <https://doi.org/10.1002/cncr.20312>.
- Speirs V, Shaaban AM. The rising incidence of male breast cancer. *Breast Cancer Res Treat*. 2009;115(2):429-430. <https://doi.org/10.1007/s10549-008-0053-y>.
- White J, Kearins O, Dodwell D, et al. Male breast carcinoma: increased awareness needed. *Breast Cancer Res*. 2011;13(5):219. <https://doi.org/10.1186/bcr2930>.
- Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. *Ann Oncol*. 2018;29(2):405-417.
- Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO Guideline. *J Clin Oncol*. 2020;38(16):1849-1863. <https://doi.org/10.1200/JCO.19.03120>.
- Andrykowski MA. Physical and mental health status and health behaviors in male breast cancer survivors: a national, population-based, case-control study. *Psychooncology*. 2012;21(9):927-934. <https://doi.org/10.1002/pon.2001>.
- Anelli TF, Anelli A, Tran KN, Lebowitz DE, Borgen PL. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. *Cancer*. 1994;74(1):74-77. [https://doi.org/10.1002/1097-0142\(19940701\)74:1<74::AID-CNCR2820740113>3.0.CO;2-%23](https://doi.org/10.1002/1097-0142(19940701)74:1<74::AID-CNCR2820740113>3.0.CO;2-%23).
- Visram H, Kanji F, Dent SF. Endocrine therapy for male breast cancer: rates of toxicity and adherence. *Curr Oncol*. 2010;17(5):17-21. <https://doi.org/10.3747/co.v17i5.631>.
- Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. *Ann Oncol*. 2012;23(6):1471-1474. <https://doi.org/10.1093/annonc/mdr459>.
- Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. *Breast Cancer Res Treat*. 2012;136(2):495-502. <https://doi.org/10.1007/s10549-012-2286-z>.
- Bootsma TI, Duijveman P, Pijpe A, et al. Unmet information needs of men with breast cancer and health professionals. *Psychooncology*. 2020;29(5):851-860. <https://doi.org/10.1002/pon.5356>.
- Kipling M, Ralph JE, Callanan K. Psychological impact of male breast disorders: literature review and survey results. *Breast Care (Basel)*. 2014;9(1):29-33. <https://doi.org/10.1159/000358751>.
- EORTC Quality of Life, Questionnaires. Accessed 1 July 2022. <https://qol.eortc.org/questionnaires/>
- Foley RN, Parfrey PS. Randomized controlled trials 4: Planning, analysis, and interpretation of quality-of-life studies. *Methods Mol Biol*. 2021;2249:247-259. [https://doi.org/10.1007/978-1-0716-1138-8\\_14](https://doi.org/10.1007/978-1-0716-1138-8_14).
- Hinz A, Singer S, Brähler E. European reference values for the quality of life questionnaire EORTC QLQ-C30: Results of a German investigation and a summarizing analysis of six European general population normative studies. *Acta Oncol*. 2014;53(7):958-965. <https://doi.org/10.3109/0284186x.2013.879998>.
- Mierzynska J, Taye M, Pe M, et al; EORTC and EORTC Breast Cancer Group. Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. *Eur J Cancer*. 2020;125(1):69-82. <https://doi.org/10.1016/j.ejca.2019.10.031>.
- Ruddy KJ, Giobbie-Hurder A, Giordano SH, et al. Quality of life and symptoms in male breast cancer survivors. *Breast*. 2013;22(2):197-199. <https://doi.org/10.1016/j.breast.2012.12.014>.
- Kowalski C, Steffen P, Ernstmann N, et al. Health-related quality of life in male breast cancer patients. *Breast Cancer Res Treat*. 2012;133(2):753-757. <https://doi.org/10.1007/s10549-012-1970-3>.
- Cuyppers M, Lamers RED, Cornel EB, et al. The impact of prostate cancer diagnosis and treatment decision-making on health-related quality of life before treatment onset. *Support Care Cancer*. 2018;26(4):1297-1304. <https://doi.org/10.1007/s00520-017-3953-8>.
- Adam S, Feller A, Rohrmann S, Arndtet V. Health related quality of life among long-term (>5years) prostate cancer survivors by primary intervention: a systematic review. *Health Qual Life Outcomes*. 2018;16(1):22. <https://doi.org/10.1186/s12955-017-0836-0>.